lofexidine (Lucemyra)
Jump to navigation
Jump to search
Indications
Mechanism of action
- inhibits release of norepinephrine
- reduces symptoms of diarrhea, nausea/vomiting, anxiety, & malaise associated with opioid withdrawal[2]
More general terms
References
- ↑ US WorldMeds. Mar 27, 2018, FDA Advisory Committee Votes in Favor of LUCEMYRA<TM> (lofexidine) for the Mitigation of Opioid Withdrawal Symptoms. https://www.prnewswire.com/news-releases/fda-advisory-committee-votes-in-favor-of-lucemyra-lofexidine-for-the-mitigation-of-opioid-withdrawal-symptoms-300620526.html
FDA Advisory Committees Briefing Information for the March 27, 2018 Meeting of the Psychopharmacologic Drugs Advisory Committee (PDAC). https://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/PsychopharmacologicDrugsAdvisoryCommittee/ucm602415.htm - ↑ 2.0 2.1 Brooks M FDA Approves First Nonopioid Drug for Opioid Withdrawal. Medscape - May 16, 2018. https://www.medscape.com/viewarticle/896736
FDA News Release. May 16, 2018 FDA approves the first non-opioid treatment for management of opioid withdrawal symptoms in adults. https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm607884.htm